## Does One CRISPR Infusion Durably Lower Cholesterol? CTX310's 12-Month Data Says Yes

A single infusion of CTX310 — a [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9)-based gene-editing therapy targeting the ANGPTL3 gene — produced a **52.5% reduction in LDL cholesterol and a 47.8% reduction in triglycerides** at 12 months in patients treated at the highest dose, with zero serious adverse events related to therapy, according to Phase I data published September 4, 2026 in the *New England Journal of Medicine*. The 15-patient first-in-human trial, conducted at Cleveland Clinic and led by cardiologist Dr. Luke Laffin, enrolled patients with medication-resistant lipid disorders. Doses ranged from 0.1 to 0.8 mg/kg in a single infusion, preceded by corticosteroid and antihistamine pretreatment. The results were simultaneously presented at the 2026 European Society of Cardiology annual meeting.

The core finding: the lipid-lowering effect observed at two months — previously reported in November 2025 — held through 12 months at all dose levels. That durability is the clinical signal the field has been waiting for, distinguishing a permanent gene-editing approach from the repeat-dosing burden of PCSK9 inhibitors or siRNA therapies. The FDA mandates 15-year long-term safety follow-up for all gene-editing therapies, and that monitoring is now underway.

---

## What CTX310 Does and Why ANGPTL3 Is the Target

CTX310 delivers CRISPR-Cas9 machinery into hepatocytes via a single intravenous infusion. Once inside liver cells, the editing complex executes a [gene knockout](https://synbiointel.com/glossary/gene-knockin) of **ANGPTL3** — angiopoietin-like protein 3 — a regulator of lipoprotein lipase activity. Loss-of-function variants in ANGPTL3 in human populations have been associated with low LDL and triglyceride levels and a correspondingly lower burden of cardiovascular disease, making it one of the more genetically validated single-gene targets in lipid biology.

The therapeutic logic is straightforward: if natural ANGPTL3 loss-of-function is cardioprotective and apparently well-tolerated across a lifetime, an engineered knockout in adulthood should replicate those metabolic benefits. The CTX310 trial's 12-month profile — approximately 50% reduction in both LDL and triglycerides at the highest dose, durable and without serious adverse events — is consistent with that hypothesis.

For context, ANGPTL3 has also been pursued via monoclonal antibody (evinacumab) and antisense oligonucleotide approaches, both of which require repeat administration. A durable one-time edit is a fundamentally different value proposition, though the comparative long-term safety datasets won't exist for years.

---

## What the Data Show and What They Don't

**What the source reports clearly:**
- 15 patients enrolled; medication-resistant lipid disorders
- Dose range: 0.1 to 0.8 mg/kg, single infusion
- Highest dose: 52.5% LDL reduction, 47.8% triglyceride reduction at 12 months
- Approximately 50% reduction in both markers at highest dose on average
- No serious adverse events related to CTX310 through one year
- 15-year FDA-mandated safety follow-up initiated
- Published in *NEJM*, DOI: 10.1056/nejmc2609825

**What the source does not report — and what analysts will want:**
- Editing efficiency in hepatocytes (what percentage of ANGPTL3 alleles were durably knocked out)
- Off-target editing frequency — the trial's pretreatment protocol suggests immunogenicity was a concern, but no off-target threshold data are disclosed in this summary
- Which company developed or is sponsoring CTX310 — the source attributes the trial to Cleveland Clinic but does not name a commercial sponsor
- Cardiovascular outcome data — LDL and triglyceride reductions are surrogate endpoints; hard event data require larger, longer trials

The 15-patient Phase I size is appropriate for a first-in-human safety and dose-finding study, but it is far too small to draw conclusions about efficacy in the statistical sense. Dr. Laffin's own language — "we look forward to continuing to investigate this therapy in a larger number of patients" — confirms that Phase II planning is the logical next step.

---

## Industry Trajectory: What This Means for In Vivo Gene Editing

The CTX310 data arrive as the in vivo CRISPR liver-editing space is crowding rapidly. ANGPTL3, PCSK9, and TTR are the three most clinically advanced hepatocyte targets. The durability question — whether a single edit holds through 12 months — has been the credibility threshold the field needed to clear before institutional investors and large pharma business development teams would seriously model the assets.

Clearing it with a clean safety profile at 12 months, and publishing the data in *NEJM* alongside ESC presentation, substantially elevates CTX310's profile. It also raises the competitive pressure on [base editing](https://synbiointel.com/glossary/base-editing) and prime editing approaches targeting the same pathway: those platforms can claim higher editing precision and reduced indel risk, but they now need to match this durability benchmark with their own clinical data.

The 15-year safety follow-up requirement is worth flagging for enterprise buyers and investors modeling commercialization timelines. Regulatory precedent for gene-editing therapies is still being written, and the FDA's long-horizon surveillance mandate reflects genuine uncertainty about late-emerging genomic consequences — not a formality.

---

## Key Takeaways

- **52.5% LDL reduction, 47.8% triglyceride reduction** at 12 months in highest-dose patients — durable from the two-month readout first reported in November 2025
- **Single infusion** of CTX310, a CRISPR-Cas9 therapy targeting hepatic ANGPTL3; dose range 0.1–0.8 mg/kg
- **15 patients** enrolled with medication-resistant lipid disorders; **zero serious adverse events** related to therapy through one year
- Published in *New England Journal of Medicine* (DOI: 10.1056/nejmc2609825) and presented at ESC 2026
- **15-year FDA-mandated safety follow-up** is underway — a non-trivial timeline constraint for commercial planning
- Off-target editing frequency and hepatocyte editing efficiency data are not reported in the available summary — critical gaps for technical due diligence
- Durability at 12 months sets a benchmark that competing base editing and prime editing approaches targeting the same lipid pathway must now match in clinical data

---

## Frequently Asked Questions

**What is CTX310 and how does it work?**
CTX310 is an experimental CRISPR-Cas9 gene-editing therapy delivered as a single intravenous infusion. It carries the CRISPR editing machinery into liver cells, where it permanently switches off the ANGPTL3 gene. Silencing ANGPTL3 reduces both LDL cholesterol and triglycerides, two lipid markers linked to cardiovascular disease.

**How much did CTX310 lower cholesterol in the trial?**
In Cleveland Clinic's Phase I trial (15 patients), patients treated at the highest dose saw a 52.5% reduction in LDL cholesterol and a 47.8% reduction in triglycerides at 12 months after a single infusion, with no serious adverse events related to the therapy.

**Is CTX310 better than existing cholesterol drugs like PCSK9 inhibitors?**
That comparison requires Phase II/III data against active comparators. CTX310's theoretical advantage is durability — a one-time edit versus repeat injections required for PCSK9 inhibitors or siRNA therapies. The 12-month data support durable effect, but hard cardiovascular outcome data and head-to-head comparisons do not yet exist.

**What are the safety concerns with CRISPR gene-editing for cholesterol?**
The Phase I trial reported no serious adverse events related to CTX310 through one year. However, the FDA requires 15-year long-term safety follow-up for all gene-editing therapies to monitor for late-emerging genomic effects. Off-target editing frequency data were not disclosed in the available summary — this remains a key technical unknown for the field.

**What happens next for CTX310?**
Dr. Laffin indicated plans to investigate CTX310 in a larger number of patients, pointing toward Phase II trial planning. The 15-year safety monitoring program is already underway as FDA-mandated. Commercial timelines will depend on Phase II/III outcomes and the evolving regulatory framework for in vivo gene-editing therapies.